Last updated on March 2019

Abraxane With Anti-PD1/PDL1 in Cisplatin-ineligible Patients With Advanced Urothelial Cancer

Brief description of study

This is a phase 2, single arm, two-stage study of abraxane with an anti-PD1/PDL1 (pembrolizumab) in cisplatin-ineligible patients with advanced urothelial cancer.

Each cycle last 21-days. All subjects will receive abraxane via IV on Day 1 and Day 8 of each cycle. Subjects will either receive pembrolizumab (IV) on Day 1 of each cycle. Subjects may continue to receive the study regimen until they experience disease progression or unacceptable toxicity.

Clinical Study Identifier: NCT03240016

Contact Investigators or Research Sites near you

Start Over

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.